HSCA E&C Letter on Improving Competition in the Generic Marketplace
Dear Chairman Pallone and Ranking Member Walden,
I am writing to you on behalf of the Healthcare Supply Chain Association (HSCA) to thank you for your continued leadership on the important issue of drug pricing and the pressing need to stop anti-competitive abuses that keep drug prices high. HSCA shares your belief that a competitive marketplace will lower the price of generic drugs and help ensure that price spikes for critical generic drugs do not jeopardize patient access to care.
Click here to read the full letter.
Related Posts
HSCA Releases Third Annual Report on Value GPOs Deliver to the Healthcare Supply Chain
Washington, DC (March 24, 2020) – The Healthcare Supply Chain Association (HSCA),...
HSCA Statement on FDA Drug Shortages Task Force Report
Washington, DC (October 29, 2019) – Healthcare Supply Chain Association (HSCA)...
HSCA Comments to the Senate HELP Committee on Planning for the Next Pandemic
Dear Chairman Alexander and Ranking Member Murray: On behalf of the...
Group Comment Letter to FDA on Clinical Immunogenicity Considerations from Biosimilar and Interchangeable Insulin Products
Dear Commissioner Hahn, The undersigned groups share the Food and Drug...